175 related articles for article (PubMed ID: 15876401)
41. Validation of a method for non-invasive in vivo measurement of growth factor release from a local delivery system in bone.
Delgado JJ; Evora C; Sánchez E; Baro M; Delgado A
J Control Release; 2006 Aug; 114(2):223-9. PubMed ID: 16859798
[TBL] [Abstract][Full Text] [Related]
42. Statins and osteoporosis: new role for old drugs.
Jadhav SB; Jain GK
J Pharm Pharmacol; 2006 Jan; 58(1):3-18. PubMed ID: 16393459
[TBL] [Abstract][Full Text] [Related]
43. Future anti-catabolic therapeutic targets in bone disease.
Boyce BF; Xing L; Yao Z; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Ann N Y Acad Sci; 2006 Apr; 1068():447-57. PubMed ID: 16831942
[TBL] [Abstract][Full Text] [Related]
44. Non-Viral Delivery System and Targeted Bone Disease Therapy.
Qadir A; Gao Y; Suryaji P; Tian Y; Lin X; Dang K; Jiang S; Li Y; Miao Z; Qian A
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699924
[TBL] [Abstract][Full Text] [Related]
45. Complexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapy.
Majkowska A; Neves M; Antunes I; Bilewicz A
Appl Radiat Isot; 2009 Jan; 67(1):11-3. PubMed ID: 18929490
[TBL] [Abstract][Full Text] [Related]
46. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
47. Targeted drug delivery for musculoskeletal diseases.
Wang D; Miller SC; Kopecek J
Adv Drug Deliv Rev; 2005 May; 57(7):935-7. PubMed ID: 15876395
[No Abstract] [Full Text] [Related]
48. Interactions between Clinically Used Bisphosphonates and Bone Mineral: from Coordination Chemistry to Biomedical Applications and Beyond.
Gałęzowska J
ChemMedChem; 2018 Feb; 13(4):289-302. PubMed ID: 29323467
[TBL] [Abstract][Full Text] [Related]
49. [Bisphosphonates in review].
Scriba GK
Pharm Unserer Zeit; 2000 Jan; 29(1):50-6. PubMed ID: 10701313
[No Abstract] [Full Text] [Related]
50. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
Varghese OP; Sun W; Hilborn J; Ossipov DA
J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
[TBL] [Abstract][Full Text] [Related]
51. Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins.
Saito N; Murakami N; Takahashi J; Horiuchi H; Ota H; Kato H; Okada T; Nozaki K; Takaoka K
Adv Drug Deliv Rev; 2005 May; 57(7):1037-48. PubMed ID: 15876402
[TBL] [Abstract][Full Text] [Related]
52. Effects of pharmacologic agents on bone in childhood: an editorial overview.
Klein GL; Bachrach LK; Holm IA
Pediatrics; 2007 Mar; 119 Suppl 2():S125-30. PubMed ID: 17332231
[No Abstract] [Full Text] [Related]
53. Management of bisphosphonate treatment in clinical practice.
Aapro MS
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S28-32. PubMed ID: 18068488
[TBL] [Abstract][Full Text] [Related]
54. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
[TBL] [Abstract][Full Text] [Related]
55. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle.
Bertoldo F; Santini D; Lo Cascio V
Nat Clin Pract Oncol; 2007 Dec; 4(12):711-21. PubMed ID: 18037875
[TBL] [Abstract][Full Text] [Related]
56. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Vessella RL; Corey E
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
[TBL] [Abstract][Full Text] [Related]
57. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
58. Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation.
Erez R; Ebner S; Attali B; Shabat D
Bioorg Med Chem Lett; 2008 Jan; 18(2):816-20. PubMed ID: 18061452
[TBL] [Abstract][Full Text] [Related]
59. Bone health in chronic kidney disease-mineral and bone disease.
Gal-Moscovici A; Sprague SM
Adv Chronic Kidney Dis; 2007 Jan; 14(1):27-36. PubMed ID: 17200041
[TBL] [Abstract][Full Text] [Related]
60. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
Saad F; Sternberg CN
Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
